Drug intelligence / Profile preview

squalamine lactate + verteporfin

Development stage: Unknown
Lead developer: Genaera
Modality: Small Molecules
Administration: Intravenous

Overview

Combination therapy consisting of squalamine lactate (MSI-1256F) and verteporfin for the treatment of wet age-related macular degeneration (AMD). Squalamine lactate is an investigational anti-angiogenic agent that inhibits several steps in the angiogenic process, including the VEGF signal pathway, integrin expression, and cytoskeletal formation. Verteporfin is a photosensitizing agent used in photodynamic therapy (PDT). The combination aims to leverage potential synergistic effects between the systemic anti-angiogenic properties of squalamine lactate and the targeted photodynamic therapy with verteporfin.

Brand names: Evizon + Visudyne

Targets

CaM (Calmodulin)YAP1 (YES-associated protein–transcriptional enhancer factor domain complex)Neuraminidase

Beyond the preview

Go deeper on squalamine lactate + verteporfin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on squalamine lactate + verteporfin.

Explore the full profile